CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 149 enrolled
Drug / intervention
Favipiravir +2 moredrug
Likely dose
Favipiravir 1800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04346628
NCT04346628Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19

Stanford University·interventional·Posted Apr 15, 2020·Updated Jul 13, 2022

In Brief

A Phase 2 clinical trial evaluating Favipiravir, Placebo, and 1 other intervention for Sars-CoV2 and COVID-19. Completed, enrolled 149 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSars-CoV2, COVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 15, 2020
Enrollment StartJul 12, 2020
Primary CompletionApr 16, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.2 years ago

Interventions

Favipiravirdrug

Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).

Placebodrug

Placebo to match favipiravir administered orally through day 10.

Standard of care treatmentother

Standard of care treatment for COVID-19 infection